Guardant Health, Inc.GHEarnings & Financial Report
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH Q4 FY2025 Key Financial Metrics
Revenue
$281.3M
Gross Profit
$181.8M
Operating Profit
$-120.8M
Net Profit
$-128.5M
Gross Margin
64.6%
Operating Margin
-43.0%
Net Margin
-45.7%
YoY Growth
39.4%
EPS
$-1.01
Guardant Health, Inc. Q4 FY2025 Financial Summary
Guardant Health, Inc. reported revenue of $281.3M (up 39.4% YoY) for Q4 FY2025, with a net profit of $-128.5M (down 15.8% YoY) (-45.7% margin). Cost of goods sold was $99.5M, operating expenses totaled $302.6M.
Key Financial Metrics
| Total Revenue | $281.3M |
|---|---|
| Net Profit | $-128.5M |
| Gross Margin | 64.6% |
| Operating Margin | -43.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Guardant Health, Inc. Q4 FY2025 revenue of $281.3M breaks down across 4 segments, led by Oncology at $189.9M (67.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Oncology | $189.9M | 67.5% |
| Biopharma Data | $54.0M | 19.2% |
| Screening | $35.1M | 12.5% |
| Licensing Other | $2.2M | 0.8% |
Guardant Health, Inc. Revenue by Segment — Quarterly Trend
Guardant Health, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Oncology and Biopharma Data) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Oncology | $189.9M | $184.4M | $158.7M | $150.6M |
| Biopharma Data | $54.0M | $54.7M | $56.0M | $45.4M |
| Screening | $35.1M | $24.1M | $14.8M | $5.7M |
| Licensing Other | $2.2M | $2.0M | $2.6M | $1.9M |
Guardant Health, Inc. Annual Revenue by Year
Guardant Health, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $982.0M).
Guardant Health, Inc. Quarterly Revenue & Net Profit History
Guardant Health, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $281.3M | +39.4% | $-128.5M | -45.7% |
| Q3 FY2025 | $265.2M | +38.5% | $-92.7M | -35.0% |
| Q2 FY2025 | $232.1M | +30.9% | $-99.9M | -43.0% |
| Q1 FY2025 | $203.5M | +20.8% | $-95.2M | -46.8% |
| Q4 FY2024 | $201.8M | +30.2% | $-111.0M | -55.0% |
| Q3 FY2024 | $191.5M | +33.9% | $-107.8M | -56.3% |
| Q2 FY2024 | $177.2M | +29.2% | $-102.6M | -57.9% |
| Q1 FY2024 | $168.5M | +30.9% | $-115.0M | -68.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $168.5M | $177.2M | $191.5M | $201.8M | $203.5M | $232.1M | $265.2M | $281.3M |
| YoY Growth | 30.9% | 29.2% | 33.9% | 30.2% | 20.8% | 30.9% | 38.5% | 39.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.70B | $1.61B | $1.54B | $1.49B | $1.34B | $1.33B | $1.28B | $2.01B |
| Liabilities | $1.64B | $1.61B | $1.60B | $1.63B | $1.60B | $1.64B | $1.63B | $2.11B |
| Equity | $68.3M | $-1.6M | $-60.1M | $-139.6M | $-250.8M | $-305.5M | $-354.5M | $-99.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-30.3M | $-94.0M | $-51.1M | $-64.5M | $-62.7M | $-60.3M | $-35.4M | $-26.4M |